XERS
Xeris Biopharma Holdings, Inc.
Overview
Xeris Biopharma provides therapies for chronic endocrine and neurological diseases. The company commercializes three FDA-approved products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia in diabetes patients, and Keveyis for Primary Periodic Paralysis.
Xeris Biopharma Holdings, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.20B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-076 Q&A exchanges
- Q4 FY2025Earnings2026-03-0211 Q&A exchanges
- Q3 FY2025Earnings2025-11-0611 Q&A exchanges
- Q2 FY2025Earnings2025-08-078 Q&A exchanges
- Q1 FY2025Earnings2025-05-0813 Q&A exchanges
- Q4 FY2024Earnings2025-03-0622 Q&A exchanges
- Q3 FY2024Earnings2024-11-0820 Q&A exchanges
- Q2 FY2024Earnings2024-08-0815 Q&A exchanges
- Q1 FY2024Earnings2024-05-0921 Q&A exchanges
- Q4 FY2023Earnings2024-03-0621 Q&A exchanges
- Q3 FY2023Earnings2023-11-094 Q&A exchanges
- Q2 FY2023Earnings2023-08-0813 Q&A exchanges
- Q1 FY2023Earnings2023-05-0910 Q&A exchanges
- Q4 FY2022Earnings2023-03-0811 Q&A exchanges
- Q3 FY2022Earnings2022-11-0915 Q&A exchanges
- Q2 FY2022Earnings2022-08-1010 Q&A exchanges
- Q1 FY2022Earnings2022-05-1120 Q&A exchanges
- Q4 FY2021Earnings2022-03-107 Q&A exchanges
- Q3 FY2021Earnings2021-11-1017 Q&A exchanges
- Q2 FY2021Earnings2021-08-054 Q&A exchanges
- Q1 FY2021Earnings2021-05-1217 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $0.02—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $0.02 | — | — | — | — | EODHD |
Source: EODHD. XERS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks XERS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.25 | $2.12 | +6.3% | +0.7% | -1.5% |
| Q4 FY2026 | $2.13 | $2.09 | +1.9% | +3.1% | +2.7% |
| Q3 FY2026 | $2.08 | $2.00 | +3.8% | -0.4% | -2.1% |
| Q2 FY2026 | $1.97 | $1.98 | -0.7% | +4.4% | +2.0% |
| Q1 FY2025 | $2.32 | $2.25 | +2.9% | -3.2% | -2.2% |
| Q4 FY2025 | $2.23 | $2.00 | +11.3% | -3.3% | -1.2% |
| Q3 FY2025 | $2.33 | $2.05 | +13.7% | +4.9% | +6.5% |
| Q2 FY2025 | $2.20 | $2.22 | -0.7% | -1.5% | -0.8% |
| Q1 FY2024 | $2.11 | $2.06 | +2.2% | +1.2% | +4.2% |
| Q4 FY2024 | $2.32 | $2.20 | +5.3% | +5.2% | +3.3% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Maintained2026-13-15
- Q3 FY2026Maintained2026-10-15
- Q2 FY2026Suspended2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Suspended2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Steven PieperSee Remarks5 mo20 callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- John Patrick Shannon JrSee Remarks10 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
- Kevin McCullochSee Remarks1 yr 2 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
- Beth HechtSee Remarks1 yr 3 mono recorded callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Anh Tu NguyenSee Remarks1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XERS.
$ curl https://api.spokenalpha.com/v1/companies/XERSFAQ
Frequently asked about XERS
Where can I find Xeris Biopharma Holdings, Inc.'s (XERS) earnings call transcripts?
Spoken Alpha indexes XERS's earnings call transcripts at https://spokenalpha.com/companies/XERS. Each call links to attributed speakers and parsed analyst Q&A. Xeris Biopharma Holdings, Inc.'s own investor relations page is at https://www.xerispharma.com/investor-relations.
When was Xeris Biopharma Holdings, Inc.'s most recent earnings call?
Xeris Biopharma Holdings, Inc. (XERS) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is XERS in?
Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).